Influence of Trough Serum Levels and Immunogenicity on Long-term Outcome of Adalimumab Therapy in Crohn's Disease-Reference-Cited by-同舟云学术

Influence of Trough Serum Levels and Immunogenicity on Long-term Outcome of Adalimumab Therapy in Crohn's Disease

Published:2009-11 Issue:5 Volume:137 Page:1628-1640
ISSN:0016-5085
Container-title:Gastroenterology
language:en
Short-container-title:Gastroenterology

Author:

Karmiris Konstantinos,Paintaud Gilles,Noman Maja,Magdelaine–Beuzelin Charlotte,Ferrante Marc,Degenne Danielle,Claes Karolien,Coopman Tamara,Van Schuerbeek Nele,Van Assche Gert,Vermeire Severine,Rutgeerts Paul

Publisher

Elsevier BV

Subject

Gastroenterology,Hepatology

Reference28 articles.

1. Incidence of inflammatory bowel disease across Europe: is there a difference between north and south?;Shivananda;Gut,1996

2. Inflammatory bowel disease: clinical aspects and established and evolving therapies;Baumgart;Lancet,2007

3. Tumor necrosis factor: biology and therapeutic inhibitors;Papadakis;Gastroenterology,2000

4. A short-term study of chimeric monoclonal antibody cA2 to tumor necrosis factor alpha for Crohn's disease;Targan;N Engl J Med,1997

5. Maintenance infliximab for Crohn's disease: the ACCENT I randomized trial;Hanauer;Lancet,2002

Cited by 454 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Aktualisierte S3-Leitlinie „Diagnostik und Therapie des Morbus Crohn“ der Deutschen Gesellschaft für Gastroenterologie, Verdauungs- und Stoffwechselkrankheiten (DGVS) (Version 4.1) – living guideline;Zeitschrift für Gastroenterologie;2024-08

2. Comparison of Endoscopic Healing and Durability between Combination Therapy with Infliximab and Azathioprine versus Infliximab Monotherapy in Pediatric Crohn's disease;2024-06-25

3. Neurological disorders following the use of tumor necrosis factor-α inhibitors in inflammatory bowel disease patients: a real-world pharmacovigilance analysis;Expert Opinion on Drug Safety;2024-05-23

4. Monitorización terapéutica de los fármacos biológicos en la enfermedad inflamatoria intestinal. Documento de Posicionamiento del Grupo Español de Trabajo en Enfermedad de Crohn y Colitis Ulcerosa (GETECCU);Gastroenterología y Hepatología;2024-05

5. Therapeutic drug monitoring in inflammatory bowel diseases. Position statement of the Spanish Working Group on Crohn’s Disease and Ulcerative Colitis;Gastroenterología y Hepatología (English Edition);2024-05